Becton Dickinson Long Term Debt 2010-2022 | BDX

Becton Dickinson long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.
  • Becton Dickinson long term debt for the quarter ending June 30, 2022 was $14.683B, a 6.48% decline year-over-year.
  • Becton Dickinson long term debt for 2021 was $17.11B, a 0.66% decline from 2020.
  • Becton Dickinson long term debt for 2020 was $17.224B, a 4.74% decline from 2019.
  • Becton Dickinson long term debt for 2019 was $18.081B, a 4.3% decline from 2018.
Becton Dickinson Annual Long Term Debt
(Millions of US $)
2021 $17,110
2020 $17,224
2019 $18,081
2018 $18,894
2017 $18,667
2016 $10,550
2015 $11,370
2014 $3,768
2013 $3,763
2012 $3,761
2011 $2,485
2010 $1,495
2009 $1,488
Becton Dickinson Quarterly Long Term Debt
(Millions of US $)
2022-06-30 $14,683
2022-03-31 $17,584
2021-12-31 $16,360
2021-09-30 $17,110
2021-06-30 $15,700
2021-03-31 $17,718
2020-12-31 $16,082
2020-09-30 $17,224
2020-06-30 $17,090
2020-03-31 $16,809
2019-12-31 $16,949
2019-09-30 $18,081
2019-06-30 $18,016
2019-03-31 $17,556
2018-12-31 $17,817
2018-09-30 $18,894
2018-06-30 $20,350
2018-03-31 $22,589
2017-12-31 $22,095
2017-09-30 $18,667
2017-06-30 $18,563
2017-03-31 $9,082
2016-12-31 $9,043
2016-09-30 $10,550
2016-06-30 $10,561
2016-03-31 $10,864
2015-12-31 $10,858
2015-09-30 $11,370
2015-06-30 $11,367
2015-03-31 $12,128
2014-12-31 $9,940
2014-09-30 $3,768
2014-06-30 $3,768
2014-03-31 $3,764
2013-12-31 $3,764
2013-09-30 $3,763
2013-06-30 $3,763
2013-03-31 $3,762
2012-12-31 $3,762
2012-09-30 $3,761
2012-06-30 $3,761
2012-03-31 $3,964
2011-12-31 $3,972
2011-09-30 $2,485
2011-06-30 $2,485
2011-03-31 $2,484
2010-12-31 $2,485
2010-09-30 $1,495
2010-06-30 $1,493
2010-03-31 $1,490
2009-12-31 $1,488
2009-09-30 $1,488
2009-06-30 $1,484
2009-03-31 $748
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $72.810B $20.248B
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $50.991B 14.81
AmerisourceBergen (ABC) United States $30.314B 13.39
West Pharmaceutical Services (WST) United States $24.398B 37.15
Laboratory Of America Holdings (LH) United States $23.439B 10.25
Cardinal Health (CAH) United States $16.828B 12.92
Cooper (COO) United States $16.065B 24.73
CONMED (CNMD) United States $2.967B 29.25
Invacare (IVC) United States $0.033B 0.00